By Colin Kellaher
Repligen has acquired 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology applications for $70 million in cash.
Repligen, a Waltham, Mass., life-sciences company, on Tuesday said the acquired assets include Maverick and Maven for real-time monitoring and control of critical bioprocess parameters; Rebel, an at-line cell culture media analyzer; and ZipChip, a sample separations device used in the characterization of product quality attributes.
908 Devices, a Boston-based provider of devices for chemical analysis, said it will focus on growth of its handheld device portfolio for vital health and safety applications.
The company said the divestiture bolsters its balance sheet and pulls forward its profitability timeline, adding that it now expects to achieve positive adjusted Ebitda by the fourth quarter of this year and positive cash flow in 2026.
Trading in shares of 908 Devices was halted premarket on Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 04, 2025 07:55 ET (12:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。